You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


OKYO Pharma reveals update on dry eye disease candidate

OKYO Pharma – a company focused on drug development in ophthalmology – has announced that its dry eye disease (DED) candidate will be used in a forthcoming phase 2 trial.